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| INTRODUC TI ON
Thrombin is the final common enzyme of the coagulation cascade and is responsible for fibrin polymerization and clot formation.
Impaired thrombin generation is typically seen in acquired hemostatic abnormalities commonly caused by liver disease, major trauma, critical illness, and dilutional coagulopathy, and can aggravate ongoing bleeding or increase the risk of bleeding. These abnormalities present singly or as variable combinations of coagulopathy, thrombocytopenia, hypofibrinogenemia, and hyperfibrinolysis. 1 Restoration of thrombin generation (TG) and clot formation are vital for arresting or preventing bleeding. Treatments for these abnormalities include plasma or prothrombin complex concentrates (PCCs), platelet transfusions, fibrinogen or cryoprecipitate infusions, and tranexamic acid.
Treatment is instituted either prophylactically to prevent periprocedural bleeding or therapeutically for the management of active bleeding. The pathogenesis of bleeding in these situations is multifactorial, and patients often receive more than 1 form of therapy for correction of abnormalities. Thresholds have been defined by various guidelines for transfusion of plasma, PCC, platelets, cryoprecipitate, fibrinogen, and tranexamic acid. [2] [3] [4] [5] [6] [7] [8] However, there are very few data available on the interaction between the various deficient components and TG and clot formation.
Adequate TG is dependent on the interaction of the procoagulant and anticoagulant pathways along with platelets and tissue factor-bearing cells. 9 Increasing platelet count and prothrombin concentration independently demonstrate significant impacts on the rate and magnitude of TG. 10, 11 Variation in levels of prothrombin and antithrombin within the normal range cause significant changes in the rate, peak, and total amount of thrombin generated in in vitro models. 12, 13 Similarly, decreasing platelet counts have been associated with lower maximal rate of TG, lower peak, and time to peak (TTP) thrombin in models of thrombocytopenia, particularly at counts < 50 × 10 9 /L. 14 The rate of TG and peak TG continue to increase until a platelet count of 300 to 500 × 10 
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The use of prohemostatic agents for management of thrombocytopenia is not a new concept. In a small clinical study, administration of recombinant factor VIIa (rFVIIa) stopped overt bleeding in 6 of 8 patients with severe thrombocytopenia. 17 In the context of impaired platelet-dependent TG, demonstrable with thrombocytopenia, we hypothesized that the addition of 
| METHODS

| Study design
| Venous blood collection and sample preparation
| PCC concentration for spiking experiments
The PCC used was Beriplex (CSL Behring, Marburg, Germany) containing procoagulant proteins factor II (prothrombin), factor VII, factor IX, and factor X; anticoagulant proteins C and S; and small quantities of antithrombin and heparin. 20 Since even small quantities of heparin interfere with the coagulation assays, 21 it was neutralized with Hepzyme (removes ≤ 2 USP U/mL unfractionated heparin from 1 mL plasma; Dade Behring/Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany), and removal was confirmed by an anti-Xa heparin assay. 22 Clotting factors were measured and found not to be affected by Hepzyme treatment (results not shown).
Beriplex was reconstituted according to the manufacturer's instructions and, following treatment with Hepzyme, frozen in aliquots at −45°C.
In line with PCC labeling, the assigned factor IX potency was used as the reference for quantifying the amount of PCC used for spiking; hereafter, the strength of PCC concentration refers to the labeled potency. The concentration of factor IX in the reconstituted lot of PCC after treatment with heparinase was 23 IU/mL, while the concentrations of prothrombin, factor X, factor VII, protein C, and protein S were 22, 30, 19, 30 , and 25 IU/mL, respectively, as measured by 1-stage clotting assays (prothrombin, factor VII, factor IX, and factor X), chromogenic assay (protein C activity), and latex antigen (free protein S).
Four concentrations of PCCs were used in the spiking experiments, and the lowest strength was 3. for all experiments, and the interrun variability was 11% for the PH and 16% for AUC.
| Ex vivo spiking of patient samples-thrombin generation assay
Ten milliliters of blood from patients was collected into 3.2% sodium citrate tubes to which CTI had been added, as described above, and left at room temperature for 30 minutes. TG assays were performed on patients' PRP on the Spectramax without adjustment of platelet counts as for the normal donor samples, with and without PCC. 
| Statistical analysis
| Thrombocytopenic patient blood samples following ex vivo spiking with PCCs show increases in thrombin generation
The findings in the in vitro thrombocytopenic model generated from healthy volunteers were replicated in PRP samples from patients with thrombocytopenia and varying severity of coagulopathy.
Whole blood samples from patients with normal INR and low platelet counts secondary to chemotherapy between 7 and 73 × 10 
| DISCUSSION
Thrombin generation in plasma is influenced by both platelets and coagulation factors. High levels of coagulation factors, in particular prothrombin, and high platelet counts are associated with an increased rate of TG (V max ), shorter TTP, higher peak thrombin, and increased quantity of thrombin (AUC). 10, 11, 13, 26 We have dem- /L, the effect of increasing platelet count appears to plateau. PCCs at 0.26 IU/mL resulted in normalization of the TG assay, and at 0.52 IU/mL resulted in about a 1-fold increase in TG when compared to TG achieved at 150 × 10 9 /L without PCC. At the same platelet count, the 2 higher concentrations resulted in TG parameters that were suggestive of hypercoagulability. AUC, area under the curve; PCC, prothrombin complex concentrate; PH, peak height; PPP, platelet-poor plasma; PRP, platelet-rich plasma; TG, thrombin generation; TTP, time to peak; V max , maximum velocity previously been demonstrated by other groups. 28 We believe that the significant effect of the PCCs was related to the prothrombin levels. In a cell-based model of coagulation, near maximal TG was seen with factor X levels of around 10%, and the rate, peak, and AUC of TG continued to increase in a near-linear fashion as the concentration of prothrombin was increased, with no evidence of saturation of the prothrombinase complex. 26 However, in a porcine model of dilutional coagulopathy, PCC administration was associated with a sustained increase in TG, unlike recombinant human prothrombin, which produced a transient increase. Furthermore, administration of PCC resulted in an improvement in all TG parameters, unlike rFVIIa, which demonstrated shortened lag time and increased rate of TG with no influence on PH or AUC. 14, 30 Our study has some important limitations. It is an in vitro laboratory study and may be disproportionately sensitive to spiking with PCCs.
The use of PCCs to compensate for severe thrombocytopenia does not take into consideration the role of platelets in primary hemostasis.
While TG tests are informative with regard to mechanisms, they do not necessarily reflect the bleeding situation. We have not undertaken 
